AXSM Stock Down Despite ADHD Study Meeting Primary Endpoint

Axsome Therapeutics (AXSM) announced that the phase III FOCUS study, which evaluated solriamfetol for the treatment of attention deficit hyperactivity disorder (ADHD), has met its primary and key secondary endpoints.Axsome currently markets solriamfetol as Sunosi for treating narcolepsy.Axsome acquired U.S. rights to Sunosi from Jazz Pharmaceuticals (JAZZ) in May 2022. It began selling Sunosi in the U.S. market in May 2022 and in certain international markets in November 2022.Jazz had received approval for ...